CompaniesStemcentrx

Stemcentrx

defunct
About

Defunct Company

Areas of Focus

Categories

Terminally AcquiredBankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (4)
View all

Total Trials

4

As Lead Sponsor

4

As Collaborator

0

Total Enrollment

237

By Phase

PHASE1: 3PHASE1/PHASE2: 1

By Status

COMPLETED: 2TERMINATED: 2
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2012
2013
2014
2015
2016
2017
2018
2019
2020
Today
NCT01901653
NCT02500914
NCT02539719
NCT02874664
Hover over trial bars to see details

Recent Trials

NCT02874664Lead Sponsor
A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer
PHASE1Completed
46 participants
Started: Sep 30, 2016 · Completed: Sep 12, 2018
NCT02539719Lead Sponsor
Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer
PHASE1Terminated
74 participants
Started: Aug 31, 2015 · Completed: Jan 2, 2019
NCT02500914Lead Sponsor
SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma
PHASE1Terminated
35 participants
Started: Jun 30, 2015 · Completed: Aug 23, 2018
NCT01901653Lead Sponsor
Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer
PHASE1/PHASE2Completed
82 participants
Started: Jul 31, 2013 · Completed: Nov 28, 2016
Stemcentrx | Biotech Hunter | Biotech Hunter